Abstract：
OBJECTIVE: To study the efficacy and side-effect profile of topical 5-Fluorouracil (5-FU) in the treatment of ocular surface squamous neoplasia (OSSN).
METHODS: Retrospective study of 101 eyes of 100 patients treated with 5-FU with one week on and 3 weeks off regimen.
RESULTS: Of the 100 patients (101 eyes), the mean age at diagnosis of OSSN was 49 (median, 52 years; range, 11-87 years). History of prior intervention was noted in 6 (6%) eyes. Tumor epicenter included bulbar conjunctiva (n = 54; 53%), limbus (n = 27; 27%), and cornea (n = 20;20%). Mean number of cycles of topical 5-FU administered was 3 (median, 3; range, 1-8). Complete tumor regression was achieved with topical 5-FU in 89 (88%) eyes with a mean number of 2 cycles (median, 2; range, 1-6) of 5-FU. The remaining 12 (12%) lesions underwent additional treatment including excisional biopsy (n = 7), extended enucleation (n = 3), and topical Interferon alpha 2b (n = 2) for complete tumor control. Over a mean follow-up period of 6 months (median, 5 months; range, 1-36 months) following treatment, tumor recurrence was noted in 2 (2%) patients, and side-effects were noted in 7 (7%) eyes including conjunctival hyperemia (n = 1), punctal stenosis (n = 1), sterile keratitis (n = 4), and limbal stem cell deficiency (n = 1).
CONCLUSIONS: Topical 5-FU is an effective non-invasive therapy for OSSN with a minimal side-effect profile.
METHODS: Retrospective study of 101 eyes of 100 patients treated with 5-FU with one week on and 3 weeks off regimen.
RESULTS: Of the 100 patients (101 eyes), the mean age at diagnosis of OSSN was 49 (median, 52 years; range, 11-87 years). History of prior intervention was noted in 6 (6%) eyes. Tumor epicenter included bulbar conjunctiva (n = 54; 53%), limbus (n = 27; 27%), and cornea (n = 20;20%). Mean number of cycles of topical 5-FU administered was 3 (median, 3; range, 1-8). Complete tumor regression was achieved with topical 5-FU in 89 (88%) eyes with a mean number of 2 cycles (median, 2; range, 1-6) of 5-FU. The remaining 12 (12%) lesions underwent additional treatment including excisional biopsy (n = 7), extended enucleation (n = 3), and topical Interferon alpha 2b (n = 2) for complete tumor control. Over a mean follow-up period of 6 months (median, 5 months; range, 1-36 months) following treatment, tumor recurrence was noted in 2 (2%) patients, and side-effects were noted in 7 (7%) eyes including conjunctival hyperemia (n = 1), punctal stenosis (n = 1), sterile keratitis (n = 4), and limbal stem cell deficiency (n = 1).
CONCLUSIONS: Topical 5-FU is an effective non-invasive therapy for OSSN with a minimal side-effect profile.
摘要：
目的：研究局部5-氟尿嘧啶（5-FU）治疗眼表鳞状细胞瘤（OSSN）的疗效和副作用。
方法：回顾性研究100例接受5-FU治疗1周和3周治疗的患者的101只眼。
结果：在100名患者（101只眼）中，诊断OSSN的平均年龄为49岁(中位数，52年；范围，11-87岁）。在6只（6％）眼中记录了先前的干预史。肿瘤中心包括球结膜（n=54；53%），角膜缘(n=27；27%)，和角膜(n=20;20%)。局部施用5-FU的平均周期数为3（中位数，3;范围,1-8).通过局部5-FU在89只（88％）眼睛中实现了完全的肿瘤消退，平均2个周期（中位数，2;范围,1-6）的5-FU。其余12例（12%）病变接受额外治疗，包括切除活检（n=7），延长摘除(n=3)，和局部干扰素α2b（n=2）用于完全控制肿瘤。在平均6个月的随访期内(中位数，5个月；范围，1-36个月)治疗后，2例（2%）患者出现肿瘤复发，7只（7％）眼睛出现副作用，包括结膜充血（n=1），泪点狭窄（n=1），无菌性角膜炎（n=4），角膜缘干细胞缺乏（n=1）。
结论：外用5-FU是一种有效的非侵入性治疗OSSN，副作用最小。
方法：回顾性研究100例接受5-FU治疗1周和3周治疗的患者的101只眼。
结果：在100名患者（101只眼）中，诊断OSSN的平均年龄为49岁(中位数，52年；范围，11-87岁）。在6只（6％）眼中记录了先前的干预史。肿瘤中心包括球结膜（n=54；53%），角膜缘(n=27；27%)，和角膜(n=20;20%)。局部施用5-FU的平均周期数为3（中位数，3;范围,1-8).通过局部5-FU在89只（88％）眼睛中实现了完全的肿瘤消退，平均2个周期（中位数，2;范围,1-6）的5-FU。其余12例（12%）病变接受额外治疗，包括切除活检（n=7），延长摘除(n=3)，和局部干扰素α2b（n=2）用于完全控制肿瘤。在平均6个月的随访期内(中位数，5个月；范围，1-36个月)治疗后，2例（2%）患者出现肿瘤复发，7只（7％）眼睛出现副作用，包括结膜充血（n=1），泪点狭窄（n=1），无菌性角膜炎（n=4），角膜缘干细胞缺乏（n=1）。
结论：外用5-FU是一种有效的非侵入性治疗OSSN，副作用最小。
